Life-threatening acute pneumonitis in mixed connective tissue disease: a case report and literature review

Rath, Eva; Zandieh, Shahin; Löckinger, Alexander; Hirschl, Mirko; Klaushofer, Klaus; Zwerina, Jochen

doi:10.1007/s00508-015-0823-6

Cited by 3 publications

(1 citation statement)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…116,117 Severe ILD is often treated with oral or IV cyclophosphamide. 118,119 Novel biological agents have been reported in the literature, but evidence is limited in quality and quantity. Imatinib was described as being effective in a 64-year-old woman with MCTD and rapidly progressive pulmonary fibrosis.…”

Section: Mixed Connective Tissue Disease Ildmentioning

confidence: 99%

Treatment of the Connective Tissue Disease–Related Interstitial Lung Diseases: A Narrative Review

Gao

Moua

2020

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a frequent complication of patients with connective tissue disease (CTD) and significantly affects morbidity and mortality. Disease course may vary from stable or mildly progressive to more severe, with rapid loss of lung function. We conducted a search of PubMed (National Library of Medicine) and the Web of Science Core Collection using the key words lung, pulmonary, pneumonia, pneumonitis, and alveolar and subtypes of CTD. All clinical studies from January 1, 1980, through September 1, 2018, were reviewed for descriptions of specific therapies and their efficacy or safety and were categorized as controlled interventional trials, observational prospective or retrospective cohort studies, case series (>5 patients), and case reports (<5 patients). Lowquality reports (<5 patients) before 2000, reviews, editorials, popular science papers, and letters to the editor without complete descriptions of the therapies used or their outcomes were excluded. Directed therapy for CTD-ILD is dominated by empirical use of immunosuppressive agents, with the decision to treat, treatment choice, and treatment duration limited to cases and cohort observations. Only a few higher-level controlled studies were available specifically in scleroderma-related ILD. We summarize herein for the clinician the published treatment scope and experience, highlighted clinical response, and common adverse reactions for the management of CTD-ILD.

show abstract

Section: Mixed Connective Tissue Disease Ildmentioning

confidence: 99%